Scott McClellan, MD, on Current Trends and Future Trajectories in Cell Therapy
The chief medical officer of Orca Bio discussed some trends he was excited about at ASH’s 2023 conference.
This is the second part of an interview with Scott McClellan, MD. For the first part,
“It's entirely speculative, but I think this field is going to change drastically.”
The past several years have seen the emergence of chimeric antigen receptor T-cell (CAR-T) therapies as a modality of increasing importance in oncology, especially for hematological malignancies. As FDA-approved CAR-T therapies have become a part of the current landscape of care in the field, interest in developing additional new cell therapies, both CAR-T therapies and other forms of cell therapy, has continued among experts in both oncology and hematology. For example, Orca Bio is currently developing Orca-T and Orca-Q, 2 engineered cell therapies that are intended to address needs that are currently not met by allogeneic hematopoietic stem cell transplants (alloHSCT), one of the standard of care options for several types of hematological malignancies.
Following
REFERENCES
1. Orca Bio presents positive data demonstrating the potential for Orca-T and Orca-Q to expand treatment to additional patient groups at the 65th ASH annual meeting. News release. Orca Bio. December 9, 2023. Accessed December 11, 2023. https://orcabio.com/orca-bio-presents-positive-data-demonstrating-the-potential-for-orca-t-and-orca-q-to-expand-treatment-to-additional-patient-groups-at-the-65th-ash-annual-meeting/
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025